請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17951
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳信銘(Hsin-Ming Chen) | |
dc.contributor.author | Kang-Shuo Chang | en |
dc.contributor.author | 張剛碩 | zh_TW |
dc.date.accessioned | 2021-06-08T00:46:54Z | - |
dc.date.copyright | 2015-09-24 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-07-28 | |
dc.identifier.citation | 1. Kubler, A.C., Photodynamic therapy. Medical Laser Application, 2005. 20: p. 37–45.
2. Mitra, A. and G.I. Stables, Topical photodynamic therapy for non-cancerous skin conditions. Photodiagnosis Photodyn Ther, 2006. 3(2): p. 116-27. 3. Weishaupt, K.R., C.J. Gomer, and T.J. Dougherty, Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res, 1976. 36(7 PT 1): p. 2326-9. 4. Schuitmaker, J.J., et al., Photodynamic therapy: a promising new modality for the treatment of cancer. J Photochem Photobiol B, 1996. 34(1): p. 3-12. 5. Castano, A.P., T.N. Demidova, and M.R. Hamblin, Mechanisms in photodynamic therapy: Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn Ther, 2005. 2(2): p. 91-106. 6. Moan, J., [Photochemotherapy of cancer]. Tidsskr Nor Laegeforen, 1991. 111(24): p. 2962-5. 7. Moan, J. and K. Berg, The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol, 1991. 53(4): p. 549-53. 8. Lobel, J., et al., 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) in a nude rat glioma model: implications for photodynamic therapy. Lasers Surg Med, 2001. 29(5): p. 397-405. 9. Oleinick, N.L., R.L. Morris, and I. Belichenko, The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci, 2002. 1(1): p. 1-21. 10. Alexiades-Armenakas, M., Laser-mediated photodynamic therapy. Clin Dermatol, 2006. 24(1): p. 16-25. 11. Lipson, R.L. and E.J. Baldes, The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatol, 1960. 82: p. 508-16. 12. Castano, A.P., T.N. Demidova, and M.R. Hamblin, Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn Ther, 2004. 1(4): p. 279-93. 13. De Rosa, F.S. and M.V. Bentley, Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives. Pharm Res, 2000. 17(12): p. 1447-55. 14. Kelty, C.J., et al., The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis. Photochem Photobiol Sci, 2002. 1(3): p. 158-68. 15. Kennedy, J.C. and R.H. Pottier, Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B, 1992. 14(4): p. 275-92. 16. Dailey, H.A. and A. Smith, Differential interaction of porphyrins used in photoradiation therapy with ferrochelatase. Biochem J, 1984. 223(2): p. 441-5. 17. Leibovici, L., et al., Activity of porphobilinogen deaminase in peripheral blood mononuclear cells of patients with metastatic cancer. Cancer, 1988. 62(11): p. 2297-300. 18. Kondo, M., et al., Heme-biosynthetic enzyme activities and porphyrin accumulation in normal liver and hepatoma cell lines of rat. Cell Biol Toxicol, 1993. 9(1): p. 95-105. 19. Hinnen, P., et al., Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus. Br J Cancer, 1998. 78(5): p. 679-82. 20. Gibson, S.L., et al., A regulatory role for porphobilinogen deaminase (PBGD) in delta-aminolaevulinic acid (delta-ALA)-induced photosensitization? Br J Cancer, 1998. 77(2): p. 235-42. 21. D'Hallewin, M.A., H. Vanherzeele, and L. Baert, Fluorescence detection of flat transitional cell carcinoma after intravesical instillation of aminolevulinic acid. Am J Clin Oncol, 1998. 21(3): p. 223-5. 22. Guyon, L., et al., Photodiagnosis and photodynamic therapy of peritoneal metastasis of ovarian cancer. Photodiagnosis Photodyn Ther, 2012. 9(1): p. 16-31. 23. Loning, M., et al., Laparoscopic fluorescence detection of ovarian carcinoma metastases using 5-aminolevulinic acid-induced protoporphyrin IX. Cancer, 2004. 100(8): p. 1650-6. 24. Piotrowski, W.J., et al., Inhalations of 5-ALA in photodynamic diagnosis of bronchial cancer. Monaldi Arch Chest Dis, 2004. 61(2): p. 86-93. 25. Stummer, W., et al., Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien), 1998. 140(10): p. 995-1000. 26. Pichlmeier, U., et al., Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol, 2008. 10(6): p. 1025-34. 27. Stummer, W., et al., Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol, 2006. 7(5): p. 392-401. 28. Peng, Q., et al., 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer, 1997. 79(12): p. 2282-308. 29. Inoue, H., et al., Massive apoptotic cell death of human glioma cells via a mitochondrial pathway following 5-aminolevulinic acid-mediated photodynamic therapy. J Neurooncol, 2007. 83(3): p. 223-31. 30. Karmakar, S., et al., 5-Aminolevulinic acid-based photodynamic therapy suppressed survival factors and activated proteases for apoptosis in human glioblastoma U87MG cells. Neurosci Lett, 2007. 415(3): p. 242-7. 31. Kawaii, S., et al., HL-60 differentiating activity and flavonoid content of the readily extractable fraction prepared from citrus juices. J Agric Food Chem, 1999. 47(1): p. 128-35. 32. Renugadevi, J. and S.M. Prabu, Cadmium-induced hepatotoxicity in rats and the protective effect of naringenin. Exp Toxicol Pathol, 2010. 62(2): p. 171-81. 33. Sabarinathan, D., P. Mahalakshmi, and A.J. Vanisree, Naringenin, a flavanone inhibits the proliferation of cerebrally implanted C6 glioma cells in rats. Chem Biol Interact, 2011. 189(1-2): p. 26-36. 34. Totta, P., et al., Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling. IUBMB Life, 2004. 56(8): p. 491-9. 35. Ekambaram, G., et al., Naringenin reduces tumor size and weight lost in N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Nutr Res, 2008. 28(2): p. 106-12. 36. Qin, L., et al., Naringenin reduces lung metastasis in a breast cancer resection model. Protein Cell, 2011. 2(6): p. 507-16. 37. Knowles, L.M., et al., Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr Cancer, 2000. 38(1): p. 116-22. 38. Galati, G., et al., Peroxidative metabolism of apigenin and naringenin versus luteolin and quercetin: glutathione oxidation and conjugation. Free Radic Biol Med, 2001. 30(4): p. 370-82. 39. Hamalainen, M., et al., Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm, 2007. 2007: p. 45673. 40. Hsiu, S.L., et al., Comparison of metabolic pharmacokinetics of naringin and naringenin in rabbits. Life Sci, 2002. 70(13): p. 1481-9. 41. Yi, L.T., et al., Involvement of monoaminergic systems in the antidepressant-like effect of nobiletin. Physiol Behav, 2011. 102(1): p. 1-6. 42. Du, G., et al., Naringenin: a potential immunomodulator for inhibiting lung fibrosis and metastasis. Cancer Res, 2009. 69(7): p. 3205-12. 43. Jung, J.W., et al., Naringenin inhibits extracellular matrix production via extracellular signal-regulated kinase pathways in nasal polyp-derived fibroblasts. Phytother Res, 2013. 27(3): p. 463-7. 44. Chen, Y.C., S.C. Shen, and H.Y. Lin, Rutinoside at C7 attenuates the apoptosis-inducing activity of flavonoids. Biochem Pharmacol, 2003. 66(7): p. 1139-50. 45. Kanno, S., et al., Effects of naringin on hydrogen peroxide-induced cytotoxicity and apoptosis in P388 cells. J Pharmacol Sci, 2003. 92(2): p. 166-70. 46. Kanno, S., et al., Effects of naringin on cytosine arabinoside (Ara-C)-induced cytotoxicity and apoptosis in P388 cells. Life Sci, 2004. 75(3): p. 353-65. 47. Kanno, S., et al., Naringenin-induced apoptosis via activation of NF-kappaB and necrosis involving the loss of ATP in human promyeloleukemia HL-60 cells. Toxicol Lett, 2006. 166(2): p. 131-9. 48. Wang, B.D., et al., Synthesis, characterization, cytotoxic activities, and DNA-binding properties of the La(III) complex with Naringenin Schiff-base. Bioorg Med Chem, 2006. 14(6): p. 1880-8. 49. Mir, I.A. and A.B. Tiku, Chemopreventive and therapeutic potential of 'naringenin,' a flavanone present in citrus fruits. Nutr Cancer, 2015. 67(1): p. 27-42. 50. Dean, M., Y. Hamon, and G. Chimini, The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res, 2001. 42(7): p. 1007-17. 51. Doyle, L.A., et al., A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A, 1998. 95(26): p. 15665-70. 52. Ross, D.D., et al., Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst, 1999. 91(5): p. 429-33. 53. Litman, T., et al., The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci, 2000. 113 ( Pt 11): p. 2011-21. 54. Polgar, O., R.W. Robey, and S.E. Bates, ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol, 2008. 4(1): p. 1-15. 55. Susanto, J., et al., Porphyrin homeostasis maintained by ABCG2 regulates self-renewal of embryonic stem cells. PLoS One, 2008. 3(12): p. e4023. 56. Kobuchi, H., et al., Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation. PLoS One, 2012. 7(11): p. e50082. 57. Jonker, J.W., et al., The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A, 2002. 99(24): p. 15649-54. 58. Desuzinges-Mandon, E., et al., ABCG2 transports and transfers heme to albumin through its large extracellular loop. J Biol Chem, 2010. 285(43): p. 33123-33. 59. Zhou, S., et al., Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood, 2005. 105(6): p. 2571-6. 60. Jonker, J.W., et al., Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX. Am J Physiol Cell Physiol, 2007. 292(6): p. C2204-12. 61. Ogino, T., et al., Serum-dependent export of protoporphyrin IX by ATP-binding cassette transporter G2 in T24 cells. Mol Cell Biochem, 2011. 358(1-2): p. 297-307. 62. Yamamoto, M., et al., Improvement of the efficacy of 5-aminolevulinic acid-mediated photodynamic treatment in human oral squamous cell carcinoma HSC-4. Acta Med Okayama, 2013. 67(3): p. 153-64. 63. Amo, T., et al., Mechanism of cell death by 5-aminolevulinic acid-based photodynamic action and its enhancement by ferrochelatase inhibitors in human histiocytic lymphoma cell line U937. Cell Biochem Funct, 2009. 27(8): p. 503-15. 64. Fukuhara, H., et al., The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer. Photodiagnosis Photodyn Ther, 2013. 10(4): p. 399-409. 65. Imai, Y., et al., Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res, 2004. 64(12): p. 4346-52. 66. Zhang, S., X. Yang, and M.E. Morris, Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol, 2004. 65(5): p. 1208-16. 67. Thomas, S., et al., CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res, 2012. 72(21): p. 5600-12. 68. Vaupel, P., O. Thews, and M. Hoeckel, Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol, 2001. 18(4): p. 243-59. 69. Wyld, L., M.W. Reed, and N.J. Brown, The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro. Br J Cancer, 1998. 77(10): p. 1621-7. 70. Georgakoudi, I., P.C. Keng, and T.H. Foster, Hypoxia significantly reduces aminolaevulinic acid-induced protoporphyrin IX synthesis in EMT6 cells. Br J Cancer, 1999. 79(9-10): p. 1372-7. 71. Matsumoto, K., et al., Effects of plasma membrane ABCB6 on 5-aminolevulinic acid (ALA)-induced porphyrin accumulation in vitro: tumor cell response to hypoxia. Photodiagnosis Photodyn Ther, 2015. 12(1): p. 45-51. 72. Brown, J.M. and W.R. Wilson, Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer, 2004. 4(6): p. 437-47. 73. Mitchell, J.B., et al., Oxygen dependence of hematoporphyrin derivative-induced photoinactivation of Chinese hamster cells. Cancer Res, 1985. 45(5): p. 2008-11. 74. Tatum, J.L., et al., Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol, 2006. 82(10): p. 699-757. 75. Brahimi-Horn, M.C. and J. Pouyssegur, The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol, 2005. 242: p. 157-213. 76. Zelzer, E., et al., Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J, 1998. 17(17): p. 5085-94. 77. Li, J., et al., Nickel compounds act through phosphatidylinositol-3-kinase/Akt-dependent, p70(S6k)-independent pathway to induce hypoxia inducible factor transactivation and Cap43 expression in mouse epidermal Cl41 cells. Cancer Res, 2004. 64(1): p. 94-101. 78. Ratcliffe, P.J., et al., Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol, 1998. 201(Pt 8): p. 1153-62. 79. Maxwell, P.H., et al., The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 1999. 399(6733): p. 271-5. 80. Feldser, D., et al., Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res, 1999. 59(16): p. 3915-8. 81. Mabjeesh, N.J. and S. Amir, Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol, 2007. 22(5): p. 559-72. 82. Marcu, L. and I. Olver, Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol, 2006. 1(1): p. 71-9. 83. Sarkar, A., et al., Naringenin and quercetin reverse the effect of hypobaric hypoxia and elicit neuroprotective response in the murine model. Brain Res, 2012. 1481: p. 59-70. 84. Goldberg, M.A., S.P. Dunning, and H.F. Bunn, Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science, 1988. 242(4884): p. 1412-5. 85. Epstein, A.C., et al., C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 2001. 107(1): p. 43-54. 86. Ivan, M., et al., HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science, 2001. 292(5516): p. 464-8. 87. Bruick, R.K. and S.L. McKnight, A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 2001. 294(5545): p. 1337-40. 88. Jaakkola, P., et al., Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 2001. 292(5516): p. 468-72. 89. Kanaya, K. and T. Kamitani, pVHL-independent ubiquitination of HIF1alpha and its stabilization by cobalt ion. Biochem Biophys Res Commun, 2003. 306(3): p. 750-5. 90. Yuan, Y., et al., Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem, 2003. 278(18): p. 15911-6. 91. Samelko, L., et al., Cobalt-alloy implant debris induce HIF-1alpha hypoxia associated responses: a mechanism for metal-specific orthopedic implant failure. PLoS One, 2013. 8(6): p. e67127. 92. Yang, D.F., et al., Topical methotrexate pretreatment enhances the therapeutic effect of topical 5-aminolevulinic acid-mediated photodynamic therapy on hamster buccal pouch precancers. J Formos Med Assoc, 2014. 113(9): p. 591-9. 93. Ji, Z., et al., Induction of hypoxia-inducible factor-1alpha overexpression by cobalt chloride enhances cellular resistance to photodynamic therapy. Cancer Lett, 2006. 244(2): p. 182-9. 94. Tomaro, M.L., J. Frydman, and R.B. Frydman, Heme oxygenase induction by CoCl2, Co-protoporphyrin IX, phenylhydrazine, and diamide: evidence for oxidative stress involvement. Arch Biochem Biophys, 1991. 286(2): p. 610-7. 95. Harmon, A.W. and Y.M. Patel, Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation. Breast Cancer Res Treat, 2004. 85(2): p. 103-10. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17951 | - |
dc.description.abstract | 在口腔癌的治療上,手術切除是最快最有效的方法但也造成顎面的缺損,即使顏面重建後,對於口腔的生理功能及外表的改變確實影響病人的生活品質。5-氨基酮戊酸光動力治療法(ALA-PDT)可用於治療口腔癌一二期的病人,其對於腫瘤細胞具有選擇性並造成癌細胞的凋亡,光動力治療法不像放射線治療會對周圍正常細胞造成傷害而導致纖維化發生,完全治療後不會有疤痕存在,更不會造成顎面的缺損,但由於ALA-PDT需要多次的治療且治療費用過高,因此尋求能增強ALA-PDT的藥物是必須的。
在有血清的環境下,細胞內ALA代謝後的光感物質PpIX會在2-3小時達到最大濃度並無法繼續累加,這被認為是PpIX與細胞運輸蛋白ABCG2作用並排出細胞外由白蛋白接收,所以ALA-PDT的效果受到ABCG2的限制。黃烷酮類的'柚皮素'被報導在K562細胞株中具有抑制ABCG2的功能,並減少抗癌藥物的排出,另有研究也指出柚皮素具有促進癌細胞凋亡的潛力且對正常細胞沒有影響,因此本篇研究結合柚皮素及ALA-PDT利用口腔癌細胞株做研究並探討其合併效果。 研究結果顯示口腔癌細胞株SAS, Ca9-22, HSC3均表現ABCG2蛋白,但柚皮素無法抑制ABCG2蛋白的表現,在功能層面上,加入ALA數個小時,柚皮素及ABCG2中和抗體皆能使SAS細胞內PpIX累積上升,且隨著時間增加能明顯上升。雖然柚皮素幾乎不抑制SAS的細胞活性也不造成細胞凋亡,但ALA-PDT與柚皮素的共同作用下更抑制SAS的細胞活性並增強細胞凋亡,且長時間的ALA處理有更好的效果。同時也發現柚皮素能增加細胞內的1O2,而高濃度的柚皮素也增加細胞內的ROS,在與ALA-PDT的共同作用下更增加1O2, ROS的量,是導致細胞死亡的可能原因。再者,為模擬低氧環境以氯化鈷處理SAS細胞,HIF-1α也因而過度表現,再加入柚皮素後隨著柚皮素濃度上升而HIF-1α表現下降,原本加入氯化鈷而導致的PpIX累積量下降也在加入柚皮素後PpIX回升,並增加光動力治療法的效果。結論,柚皮素可能具有抑制ABCG2的功能使PpIX累積增加並且增加細胞內的1O2及ROS,同時也發現柚皮素能抑制HIF-1α並回復模擬低氧的狀況使PpIX回升,增加模擬低氧狀況下光動力治療法的效果。 | zh_TW |
dc.description.abstract | Surgery is the quickest and most effective way for the oral cancer treatments, but it also causes facial defects and deformity in the surgery region. Even with reconstructive procedures, the patient’s quality of life can be significantly lowered by these functional and facial problems. 5- Aminolevulinic acid photodynamic therapy (ALA-PDT) can be used in the treatment of early oral cancers (stage I and II), and it may cause tumor cell apoptosis selectivity. Unlike radiotherapy, ALA-PDT does not affect the surrounding normal cells. There is no scar formation after treatment. However, due to the need of several ALA-PDT treatments to achieve complete response and high costs, it is necessary to find a drug that can enhance ALA-PDT efficacy.
Intracellular photosensitizer PpIX reaches the maximum concentration by 2-3 hours when treated with ALA and it is unable to accumulate PpIX in the presence of serum. It was reported that ABCG2 can transport PpIX to the extracellular albumin, and ABCG2 is believed to act as a regulator of intracellular PpIX levels. Thus, the effect of ALA-PDT is influenced by the ABCG2. Besides, flavanones naringenin has been reported to inhibit ABCG2 function and ABCG2-mediated drug efflux in K562 cell line. Several studies have demonstrated that naringenin have the potential to promote cancer cell apoptosis and had no effect on normal cells. In this study, we investigated the effect of naringenin on ALA-PDT in oral cancer cell line. In the present study, we found that oral cancer cell lines Sas, Ca9-22, Hsc-3 could express ABCG2 protein, but naringenin could not inhibit ABCG2 protein expression. In the functional assay, we blocked ABCG2 by using ABCG2 antibody or naringenin in SAS cell line. We found that the pretreatment of ABCG2 antibody or naringenin could significantly increase the PpIX level in SAS cell line when treated with ALA several hours compared to control. Although naringenin could not inhibit cell viability and induce cell apoptosis, naringenin-pretreated ALA-PDT significantly inhibited cell viability and also enhanced cell apoptosis and It became more effective when treated ALA with a longer period. Moreover, we found that naringenin could increase not only intracellular singlet oxygen but also reactive oxygen species in a high concentration. The naringenin-pretreated ALA-PDT significantly enhanced singlet oxygen and reactive oxygen species production, as a result, it was the possible cause of cell death. Furthermore, in order to simulate a hypoxia environment, SAS cells were treated with cobalt chloride. After a while, HIF-1α protein overexpressed when treated with cobalt chloride. Interestingly, when the naringenin concentration increased, HIF-1α expression decreased significantly. The situation of PpIX accumulation dropped when treated with cobalt chloride, and this could be rescued when treated with naringenin. In summary, naringenin can probably inhibit ABCG2 function that in turn cause more PpIX accumulation and increases intracellular singlet oxygen and ROS. Moreover, naringenin can rescue hypoxia-mimetic conditions and promote PpIX accumulation and further enhances the effect of ALA-PDT. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T00:46:54Z (GMT). No. of bitstreams: 1 ntu-104-R02450004-1.pdf: 5783131 bytes, checksum: 7d83b588b27f1136dfca869d59ac93e2 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 口試委員會審定書....................................................I
致謝...............................................................II 中文摘要..........................................................III 英文摘要(Abstract)................................................. V 目錄(Index)........................................................ 1 第一章 導論 (Introduction) 第一節 口腔癌 1-1 口腔癌簡介.................................................3 1-2 口腔癌診斷.................................................4 1-3 口腔癌治療.................................................5 第二節 光動力治療法(Photodynamic therapy).........................6 第三節 柚皮素(Naringenin).......................................10 第四節 ABCG2/BCRP ...............................................11 第五節 Hypoxia(低氧) ............................................12 第二章 實驗目的 (Aim)..............................................15 第三章 實驗材料與方法 (Material and Method) 第一節 細胞株來源及培養.........................................15 第二節 光動力治療照射機器.......................................16 第三節 細胞活性試驗(MTT assay)...................................17 第四節 PpIX螢光測定.............................................17 4-1 Photobleaching PpIX測定....................................18 4-2 ABCG2中和抗體的使用並測定PpIX螢光強度.....................18 第五節 ROS螢光測定..............................................18 第六節 1O2螢光測定...............................................19 第七節 Apoptosis (Annexin V-FITC/PI).............................19 第八節 低氧(Hypoxia)............................................19 第九節 西方墨點法...............................................20 第四章 實驗結果 (Results) 第一節 ALA-PDT抑制口腔癌細胞株SAS的細胞活性.....................23 第二節 柚皮素幾乎不抑制SAS的細胞活性............................23 第三節 口腔癌細胞株SAS, Ca9-22, HSC3均表現ABCG2,柚皮素不抑制ABCG2的蛋白表現......................................................24 第四節 柚皮素及ABCG2中和抗體皆能使SAS細胞內PpIX累積上升........25 第五節 SAS細胞在柚皮素的作用下PpIX的累積上升,且光動力治療後消耗掉的PpIX變多......................................................26 第六節 柚皮素與ALA-PDT共同作用下更能抑制SAS的細胞活性,且長時間的ALA處理更能增強SAS細胞凋亡......................................26 第七節 柚皮素增加SAS細胞內的ROS及1O2,與ALA-PDT共同作用更使ROS及1O2的量增加......................................................27 第八節 在低氧環境,柚皮素抑制SAS細胞HIF-1a的表現並使PpIX回升....28 第九節 柚皮素抑制氯化鈷造成的SAS細胞低氧,使1O2的量上升,增加低氧環境下的ALA-PDT效果...............................................29 第五章 討論 (Discussion)...........................................30 第六章 總結 (Conclusion)...........................................33 第七章 圖與表......................................................34 第八章 參考文獻 (References).......................................58 | |
dc.language.iso | zh-TW | |
dc.title | 柚皮素增強SAS口腔癌細胞株經5-氨基酮戊酸光動力治療法誘發細胞凋亡作用的研究 | zh_TW |
dc.title | Naringenin increased 5-aminolevulinic Acid-mediated Photodynamic Therapy induced Apoptosis in SAS Oral Cancer Cell Line | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 郭彥彬,江俊斌 | |
dc.subject.keyword | 柚皮素,5-氨基酮戊酸光動力治療法, | zh_TW |
dc.subject.keyword | Naringenin,5-ALA-PDT, | en |
dc.relation.page | 65 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2015-07-28 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 5.65 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。